Highlights Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L3006

Market Closed - Nasdaq Other stock markets 02:00:00 11/05/2024 am IST			5-day change	1st Jan Change
0.7726 ^USD	-2.81%		-0.48%	-84.25%

09/05	Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
15/03	Maxim Group Adjusts Quoin Pharmaceuticals Price Target to $4 From $15, Maintains Buy Rating	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05	CI
Quoin Pharmaceuticals Seeks M&A Opportunities	14/03	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	14/03	CI
Quoin Pharma Shares Double After FDA Grants Clearance for Teens in QRX003 Trial	04/03	DJ
Quoin Pharmaceuticals, Ltd. Announces FDA Clearance to Recruit Teen Subjects into Both Ongoing Netherton Syndrome Clinical Studies	04/03	CI
Quoin Pharmaceuticals Ltd. Files U.S. and International Patent Applications for Novel Netherton Syndrome Combination Product	08/02	CI
Quoin Pharmaceuticals Ltd. Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome	19/12	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Quoin Pharmaceuticals, Ltd. Announces Additional Positive Clinical Data from Open-Label, Single-Arm Clinical Trial in Netherton Syndrome	24/23/24	CI
Quoin Pharmaceuticals Ltd. Enters into an Exclusive License and Distribution Agreement with Farma Mondo SA	13/23/13	CI
Quoin Pharmaceuticals Limited Seeks M&A	03/23/03	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/23/03	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	09/23/09	CI
Quoin Pharmaceuticals, Ltd. Doses First Patient in Open Label Netherton Syndrome Clinical Trial	21/23/21	CI
Quoin Pharmaceuticals Seeks M&A Opportunities	09/23/09	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	09/23/09	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022	09/23/09	CI
Quoin Pharmaceuticals, Ltd. Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome	13/22/13	CI
Quoin Pharmaceuticals, Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	10/22/10	CI
Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients	18/22/18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Quoin Pharmaceuticals, Ltd.

Equities

QNRX

US74907L3006

Highlights

Filters